CN115068467A - Medical application of andrographolide as LTB4 receptor inhibitor - Google Patents
Medical application of andrographolide as LTB4 receptor inhibitor Download PDFInfo
- Publication number
- CN115068467A CN115068467A CN202110275769.4A CN202110275769A CN115068467A CN 115068467 A CN115068467 A CN 115068467A CN 202110275769 A CN202110275769 A CN 202110275769A CN 115068467 A CN115068467 A CN 115068467A
- Authority
- CN
- China
- Prior art keywords
- andrographolide
- diabetic
- complications
- ethanol
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 title claims abstract description 79
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 239000003112 inhibitor Substances 0.000 title claims abstract description 20
- 102000003680 Leukotriene B4 receptors Human genes 0.000 title claims abstract description 13
- 108090000093 Leukotriene B4 receptors Proteins 0.000 title claims abstract description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 38
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 36
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 20
- 208000008589 Obesity Diseases 0.000 claims abstract description 13
- 235000020824 obesity Nutrition 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 8
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 4
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 4
- 208000008960 Diabetic foot Diseases 0.000 claims abstract description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 244000118350 Andrographis paniculata Species 0.000 claims description 16
- 239000000287 crude extract Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims 1
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 101001017968 Homo sapiens Leukotriene B4 receptor 1 Proteins 0.000 abstract description 14
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 22
- 201000009104 prediabetes syndrome Diseases 0.000 description 22
- 208000002705 Glucose Intolerance Diseases 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 20
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 20
- 102000004877 Insulin Human genes 0.000 description 17
- 108090001061 Insulin Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 229940125396 insulin Drugs 0.000 description 17
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 235000001727 glucose Nutrition 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- -1 5-hydroxy-7,8-dimethoxyflavanone (5-hydroxy-7,8-dimethoxyflavanone) Chemical compound 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- 229960004586 rosiglitazone Drugs 0.000 description 10
- 239000011575 calcium Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 206010056997 Impaired fasting glucose Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 101100236209 Mus musculus Ltb4r gene Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- GVRNTWSGBWPJGS-YSDSKTICSA-N 4-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)CC1=CCOC1=O GVRNTWSGBWPJGS-YSDSKTICSA-N 0.000 description 4
- YTHKMAIVPFVDNU-GPTWTFMPSA-N 4-[[(1r,2r,4ar,5r,8as)-2-(3-carboxypropanoyloxy)-1,4a-dimethyl-6-methylidene-5-[(e)-2-(5-oxo-2h-furan-4-yl)ethenyl]-3,4,5,7,8,8a-hexahydro-2h-naphthalen-1-yl]methoxy]-4-oxobutanoic acid Chemical compound C(/[C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@H]([C@]2(COC(=O)CCC(O)=O)C)OC(=O)CCC(O)=O)=C\C1=CCOC1=O YTHKMAIVPFVDNU-GPTWTFMPSA-N 0.000 description 4
- 241000746375 Andrographis Species 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 230000006020 chronic inflammation Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- GVRNTWSGBWPJGS-UHFFFAOYSA-N deoxyandrographolide Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CCC1=CCOC1=O GVRNTWSGBWPJGS-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- YIIRVUDGRKEWBV-FZOOCBFYSA-N (3e)-3-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]furan-2-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/C=COC1=O YIIRVUDGRKEWBV-FZOOCBFYSA-N 0.000 description 3
- XMJAJFVLHDIEHF-UHFFFAOYSA-N 14-deoxy-11, 12-didehydroandrographolide Natural products OCC1(C)C(O)CCC2(C)C1CCC(=C)C2C=CC1=CCOC1=O XMJAJFVLHDIEHF-UHFFFAOYSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 108091006300 SLC2A4 Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- XMJAJFVLHDIEHF-YSDSKTICSA-N dehydroandrographolide Natural products C([C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@@H](O)[C@]2(CO)C)=CC1=CCOC1=O XMJAJFVLHDIEHF-YSDSKTICSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- SJKRRZPXYGTAGA-UHFFFAOYSA-N 14-deoxy-12-methoxyandrographolide Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CC(OC)C1=CCOC1=O SJKRRZPXYGTAGA-UHFFFAOYSA-N 0.000 description 2
- GVRNTWSGBWPJGS-DSJDWBEOSA-N 14-deoxyandrographolide Natural products O=C1C(CC[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@]23C)=CCO1 GVRNTWSGBWPJGS-DSJDWBEOSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- YGCYRQKJYWQXHG-RDNQFMDVSA-N 4-[2-[(1r,4as,5r,8as)-5,8a-dimethyl-2-methylidene-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@@]1(C)[C@H]2CCC(=C)[C@@H](CCC=3C(OCC=3)=O)[C@]2(C)CCC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YGCYRQKJYWQXHG-RDNQFMDVSA-N 0.000 description 2
- CZRGNFVQUYWGKP-UHFFFAOYSA-N 5-hydroxy-2-(2-hydroxyphenyl)-7,8-dimethoxychromen-4-one Chemical compound COC=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1O CZRGNFVQUYWGKP-UHFFFAOYSA-N 0.000 description 2
- AJMNTEFGXPRZHG-UHFFFAOYSA-N 5-hydroxy-7,8-dimethoxy-2-(2-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(OC)=C2O1 AJMNTEFGXPRZHG-UHFFFAOYSA-N 0.000 description 2
- IHLSBQVBFDTNTC-UHFFFAOYSA-N 5-hydroxy-7,8-dimethoxy-2-phenylchromen-4-one Chemical compound COC=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 IHLSBQVBFDTNTC-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
- 101150063696 LTB4R2 gene Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- MJBPUQUGJNAPAZ-AWEZNQCLSA-N butin Chemical compound C1([C@@H]2CC(=O)C3=CC=C(C=C3O2)O)=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-AWEZNQCLSA-N 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- MEEPUSVTMHGIPC-UHFFFAOYSA-N deoxyandrographiside Natural products OC1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O MEEPUSVTMHGIPC-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000004155 insulin signaling pathway Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- BBGWVUQBIGGVLS-UHFFFAOYSA-N neoandrographolide Natural products CC1(COC2OC(CO)C(O)C(O)C2O)C(O)CCC3(C)C(CCC4=C(O)COC4=O)C(=C)CCC13 BBGWVUQBIGGVLS-UHFFFAOYSA-N 0.000 description 2
- YGCYRQKJYWQXHG-UHFFFAOYSA-N neoandrographoside Natural products C1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O YGCYRQKJYWQXHG-UHFFFAOYSA-N 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- VPGMCCIECGDASG-ZDUSSCGKSA-N (2s)-5-hydroxy-7,8-dimethoxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C(=C3O2)OC)OC)=CC=CC=C1 VPGMCCIECGDASG-ZDUSSCGKSA-N 0.000 description 1
- LPZCCMIISIBREI-JXMPMKKESA-N (Z)-24-ethylidenelophenol Chemical compound C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC/C(=C/C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 LPZCCMIISIBREI-JXMPMKKESA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- MMXQJDQGRYTRDU-UHFFFAOYSA-N 2,5-dihydroxy-7,8-dimethoxy-2-phenyl-3H-chromen-4-one Chemical compound O1C2=C(OC)C(OC)=CC(O)=C2C(=O)CC1(O)C1=CC=CC=C1 MMXQJDQGRYTRDU-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- VPGMCCIECGDASG-CYBMUJFWSA-N 5-Hydroxy-7,8-dimethoxyflavanone Natural products C1([C@H]2CC(=O)C3=C(O)C=C(C(=C3O2)OC)OC)=CC=CC=C1 VPGMCCIECGDASG-CYBMUJFWSA-N 0.000 description 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
- XPVVXQAJUDIGAJ-UHFFFAOYSA-N 5-hydroxy-7,8-dimethoxyflavanone Natural products COc1cc(OC)c2OC(CC(=O)c2c1O)c3ccccc3 XPVVXQAJUDIGAJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VPGMCCIECGDASG-UHFFFAOYSA-N 7-O-methyldihydrowogonin Natural products O1C2=C(OC)C(OC)=CC(O)=C2C(=O)CC1C1=CC=CC=C1 VPGMCCIECGDASG-UHFFFAOYSA-N 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- FAHOXMDAEGCIOY-UHFFFAOYSA-N CC1C(=O)C2=C(C=C(C(=C2OC1(C)C3=CC=CC=C3)C)C)O Chemical compound CC1C(=O)C2=C(C=C(C(=C2OC1(C)C3=CC=CC=C3)C)C)O FAHOXMDAEGCIOY-UHFFFAOYSA-N 0.000 description 1
- 235000014138 Caesalpinia decapetala Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101001050607 Homo sapiens KH domain-containing, RNA-binding, signal transduction-associated protein 3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- 101150014540 Ltb4r gene Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100236212 Mus musculus Ltb4r2 gene Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000022275 macrophage chemotaxis Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000012237 sodium aluminium phosphate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- IQQWMJSNEUUJAY-UHFFFAOYSA-D trialuminum;sodium;dihydrogen phosphate;hydrogen phosphate;tetrahydrate Chemical compound O.O.O.O.[Na+].[Al+3].[Al+3].[Al+3].OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP([O-])([O-])=O.OP([O-])([O-])=O IQQWMJSNEUUJAY-UHFFFAOYSA-D 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of medicines, and discloses a medical application of andrographolide as an LTB4 receptor inhibitor. The andrographolide is subjected to action target research, and is found to have a remarkable inhibition effect in an LTB4R inhibitor model. Therefore, the invention discloses the application of andrographolide and pharmaceutically acceptable salts and pharmaceutical compositions thereof in preparing LTB4 receptor inhibitors and in preparing medicaments for treating obesity, insulin resistance, abnormal glucose tolerance, hyperlipidemia, diabetes and complications thereof and the like, wherein the diabetic complications comprise diabetic nephropathy, diabetic cardiovascular complications, diabetic cerebrovascular diseases, diabetic eye complications and diabetic foot.
Description
Technical Field
The invention belongs to the technical field of medicines, and relates to a method for extracting, separating and purifying andrographolide from andrographis paniculata and application of andrographolide in preparing an LTB4 receptor inhibitor; and the application in the preparation of medicaments for treating obesity, insulin resistance, abnormal glucose tolerance, hyperlipidemia, diabetes, complications thereof and the like, wherein the diabetic complications comprise diabetic nephropathy, diabetic cardiovascular complications, diabetic cerebrovascular diseases, diabetic eye complications and diabetic feet.
Background
Diabetes is a group of endocrine-metabolic diseases characterized primarily by chronic hyperglycemia, which can lead to complications in various parts of the body and increase the risk of premature death. In recent years, with the rapid development of economy in China, the aging of the population society, environmental pollution, bad life style, over-high mental stress and other factors, diabetes mellitus is increasingly worsened in China. Diabetes mellitus can hardly be completely cured, complications of diabetes mellitus can bring physiological damage to patients, mental pain, reduction in quality of life and the like, and high and continuous medical expenses can bring huge economic burden to patients and families. Therefore, research on the treatment of diabetes is imminent.
Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG) refer to blood glucose levels above the normal range but below the diagnostic criteria, collectively referred to as impaired glucose regulation, also commonly referred to as pre-diabetes. The implications of the emergence of IGT and IFG are three-fold: (1) high risk of developing type 2 diabetes; (2) increased risk of cardiovascular disease; (3) reminding to prevent disease development by intervention measures. The risk of developing type 2 diabetes from IGT and IFG is influenced by factors such as age, weight, etc., and the cumulative incidence of developing type 2 diabetes five years after diagnosing IGT or IFG is approximately 26% and 50%, respectively. Obesity, less physical activity, increased blood lipid, family history of diabetes and hyperinsulinemia are the most risk factors for inducing impaired glucose tolerance.
All type 2 diabetes patients almost pass through the stage of impaired glucose tolerance, and thus, impaired glucose tolerance is considered as a high risk group of onset of diabetes, or "pre-diabetes". Impaired glucose tolerance is often accompanied by obesity, hypertension, hyperlipidemia, and the like. Compared with normal people, the prevalence rate of hypertension and obesity is 2 times higher, and the prevalence rate of coronary heart disease is 8 times higher.
To prevent diabetes, the prevention and treatment of Impaired Glucose Tolerance (IGT) must be performed. Lifestyle changes including diet control, exercise gain, weight loss, smoking cessation, etc. are the most basic interventions. The related research reports that after the IGT patients are intervened by a life style, the incidence rate of diabetes is reduced by 58 percent after 3 years, meanwhile, the blood pressure and the body weight are obviously reduced compared with the prior art, and the incidence rate of diabetes of the IGT patients without any intervention measures is up to 68 percent. Recent intervention tests on IGT (insulin-dependent diabetes mellitus) populations show that the IGT populations subjected to drug intervention not only remarkably reduce the incidence rate of diabetes, but also remarkably reduce the risk of Cerebrovascular diseases (CVD), wherein the newly-generated hypertension is reduced by 34%, the myocardial infarction is reduced by 9%, and any cardiovascular event is reduced by 49%. Therefore, after the diagnosis of the IGT patient is definite, the physician should take a medical initiative to select an appropriate treatment scheme and drugs according to the condition of the disease, and actively treat hyperglycemia and related risk factors.
Therefore, targeted IGT intervention is taken early, helping to reverse IGT, reducing the risk of IGT progressing to diabetes, and reducing the occurrence of CVD.
Diabetes is clinically divided into 3 types: type 1, type 2 and gestational diabetes, with type 2 diabetes being the most common, accounting for about 85% -95%, and even higher. Type 2 diabetes is primarily characterized by insulin resistance. Insulin resistance is a chronic subclinical inflammatory process resulting from decreased glucose uptake and utilization efficiency due to decreased sensitivity of peripheral target tissue cells such as liver, muscle and adipose tissue to insulin. Intracellular inflammatory factors secrete factors which can weaken insulin signals, so that the transmission of the insulin signals is blocked, and insulin resistance is induced. Experimental studies of inflammatory factor and insulin resistance adiponectin levels in type 2 diabetic patients indicate that chronic inflammatory states exist in type 2 diabetic patients. Therefore, improving inflammation-induced insulin resistance and increasing insulin sensitivity has become a significant problem for the treatment of type 2 diabetes patients.
Inflammatory factor leukotriene B4(LTB4) is a leukotriene-like substance associated with inflammatory response, and is produced by sequential catalysis of arachidonic acid by 5-lipoxygenase, 5-lipoxygenase activating protein, leukotriene A4 hydrolase. LTB4 has potent chemotaxis towards macrophages, neutrophils and T cells. LTB4 can promote the development of inflammation by activating and recruiting macrophages, eosinophils, effector T cells, etc. And simultaneously can induce the formation and release of lysosomes and reactive oxygen species in the neutrophils.
LTB4 plays a role in chemotaxis by binding with G protein-coupled receptors Ltb4r1 or Ltb4r2, and regulates biological functions such as proinflammatory factor release. Ltb4r1 (also called Blt1) is a high affinity receptor specific for Ltb4, and is widely expressed in inflammatory and immune cells, including granulocytes, eosinophils, macrophages, Th1 cells, Th2 cells, Th17 cells, CD8 effector T cells, dendritic cells, osteoclasts, and the like. Ltb4r2 (also known as Blt2) is a low affinity receptor and is more widely expressed. The LTB4-Ltb4r1 system has important defense function in the acute infection stage of the host and reduces inflammatory reaction. Chronic activation of the LTB4-Ltb4r1 system can cause chronic inflammation, including atherosclerosis and arthritis, among others. A recent study showed that the Ltb4r1 gene knockout could reduce the inflammatory response and improve insulin resistance in mice. This indicates that the insulin sensitive phenotype is based on the deletion of the Ltb4r1 gene. The hyperinsulinemic-euglycemic clamp experiment also demonstrated that most mice exhibited greater insulin sensitivity after treatment with an inhibitor of Ltb4r 1.
Obesity is an important factor that leads to insulin resistance. Epidemiological studies have also shown that obesity is a significant risk factor for diabetes. Over-obesity, macrophages are activated by the over-accumulated fat, and activated macrophages release LTB4 and other inflammatory molecules to attract more macrophages. This positive feedback adjustment mechanism will produce more LTB 4. Excess LTB4 activates cells other than macrophages, such as hepatocytes, adipocytes, muscle cells, and the like, which are stimulated to develop insulin resistance. In visceral fat of obese subjects, macrophages may account for 40% of the total cell number and secrete a variety of factors that may impair insulin signaling. By using macrophage tracking technology, it was found that the degree of labeling in adipose tissue was substantially lower in mice macrophages treated with the Ltb4r1 inhibitor. LTB4 promotes monocyte migration into adipose tissue, stimulates macrophage chemotaxis in a dose-dependent manner, and promotes insulin resistance. In addition, other immune cell types, such as lymphocytes, eosinophils, and neutrophils also contribute to the inflammatory state of obese tissues. This cytokine-independent mechanism of insulin resistance provides a new mechanism for the relationship between inflammation and decreased insulin sensitivity.
From the molecular mechanism of insulin resistance, energy metabolism disorder, endoplasmic reticulum stress, oxidative stress, mitochondria function impairment, silencing information regulator signal channel down regulation, inflammatory reaction, central regulation disorder and the like are all involved in the generation of insulin resistance. The impairment of the insulin signaling pathway is essential for insulin resistance. An important function of glucose transporter 4(GLUT4) is to transport and transport glucose in adipose and muscle tissue. Studies have shown that LTB4 causes insulin resistance through inhibition of GLUT 4. LTB4 can enhance synthesis of hepatic Diacylglycerol (DAG) and ceramide, induce endoplasmic reticulum stress and increased mitochondrial membrane permeability, inhibit insulin signaling pathway, reduce insulin sensitivity, and induce insulin resistance. At the same time, increased DAG increases the risk of lipotoxicity, and is one of the important mechanisms leading to insulin resistance.
Therefore, inhibition of the action of LTB4 may be an effective treatment for insulin resistant diseases. And pharmaceutically acceptable salts and pharmaceutical compositions thereof in the treatment of obesity, impaired glucose tolerance, hyperlipidemia, diabetes and complications thereof; and the use of chronic inflammation, insulin resistance, cerebrovascular disease and atherosclerosis in relation to the above mentioned diseases.
The herba Andrographitis is dry aerial part of herba Andrographitis (Burm.F.) Nees of Acanthaceae, and is also known as herba Andrographitis, WANGBIXIANCAO, herba Swertiae Dilutae, etc. The functional indications are as follows: clear heat and remove toxicity, cool blood and relieve swelling. Can be used for treating common cold, fever, sore throat, aphtha of the mouth and tongue, cough due to cough, diarrhea, dysentery, pyretic stranguria, pain, carbuncle, swelling, sore, and snake bite.
The andrographis paniculata leaves contain diterpenes: andrographolide (andographolide) 0.6%, 14-deoxyandrographolide (14-deoxyandrographolide) 0.15%, neoandrographolide (neoandrographolide) 0.05%, 14-deoxyandrographolide-19- β -D-glucoside (14-deoxyandrographolide-19- β -D-glucoside) 0.03%, 14-deoxy-12-methoxy-andrographolide (14-deoxy-12-methoxy-andrographolide) 0.001%, and andrographolide (andrographolide) 0.03%; and (3) flavonoids: oroxylin a, wogonin (wogonin); polyphenols: caffeic acid (caffeic acid), chlorogenic acid (chlorogenic acid) and mixtures of dicaffeoylsilicic acids (mix of dicaf-femoylquinic acids).
The lotus root contains flavonoids: andrographolide (andrographin), 5, 2-dihydroxy-7, 8-dimethoxyflavone (panicolin), 3-O-methyl-widmanoflavone, i.e., 5-hydroxy-7,8,2, 3-tetramethylflavone (3-O-methoxylightning, 5-hydroxy-7,8,2, 3-tetramethyflavone), apigenin-4,7-dimethyl ether (apigenin-4, 7-dimethylflavone), 5-hydroxy-7,8-dimethoxyflavanone (5-hydroxy-7,8-dimethoxyflavanone), 5-hydroxy-3,7,8, 2-tetramethoxyflavone (5-hydroxy-3,7,8, 2-tetramethoxyflavone), 5-hydroxy-7, 8-dimethoxyflavone (5-hydroxy-7,8-dimethoxy flavanone), andrographolide A, B, C, D, E (andro-grapholide), F, and optionally alpha-sitosterol.
The andrographolide and its derivatives have wide bioactivity, and research shows that the andrographolide and its derivatives have antipyretic, anti-inflammatory, antiviral, antibacterial, liver protecting, gallbladder promoting, immunity regulating, cardiovascular disease resisting, and anti-tumor effects.
The antipyretic effect is as follows: andrographolide and andrographolide have the effects of inhibiting and delaying body temperature rise caused by Diplococcus pneumoniae and hemolytic streptococcus B, and the action strength of the latter is not as strong as that of the former. The composition has certain antipyretic effect on rabbits with fever caused by paratyphoid bacterin or rats with fever caused by 2, 4-dinitrophenol, and the dehydroandrographolide, andrographolide and dehydroandrographolide have the strongest effect.
Anti-inflammatory action: the permeability of the capillary vessels of the skin or the abdominal cavity of the mouse is increased by adopting dimethylbenzene and acetic acid, and the lavage of deoxyandrographolide or dehydroandrographolide can reduce the exudation of the capillary vessels, and compared with a control, P is less than 0.05 or P is less than 0.01. Has obvious inhibiting effect on hemorrhagic necrotic exudation caused by croton oil in rats and deoxyandrographolide.
Impact on immune function: the herba Andrographitis decoction can improve phagocytosis of Staphylococcus aureus by peripheral blood leukocyte in vitro. The andrographolide injection can also enhance phagocyte function. The in vitro experiment of 3H-thymidine infiltration into lymphocytes shows that the injection of water-soluble derivatives of Andrographis paniculata Nees has inhibitory effect on PHA-promoted 3H-thymidine infiltration.
Effects on pituitary-adrenal cortex system function: the first, second and third andrographis herbs, 4g/kg of third and fourth andrographis herbs and 1g/kg of butin are administrated to the young mouse by intragastric administration, 63-250mg/kg of dehydroandrographolide succinate (DAS) is injected into the abdominal cavity, 1 time per day, 3 days continuously, the thymus can be atrophied, which indicates that the function of adrenal cortex is strengthened.
Effects on the cardiovascular and blood systems: the experimental coronary artery thrombosis myocardial infarction dog is injected with 4g/kg of total flavone (equivalent to 4g of crude drug) by vein, and can remarkably improve epicardial electrocardiogram. Pathological examination shows that no thrombus is formed in the coronary artery, only intimal drop and little platelet aggregation and red and white blood cell adhesion are seen at the damaged coronary artery intima, and most animal myocardial sections are normal. The andrographis paniculata root total flavonoids can also obviously reduce the myocardial ytterbium uptake rate of rats and have a certain protection effect on myocardial injury caused by isoproterenol and experimental myocardial infarction ischemic injury.
Liver protection and gallbladder function: the herba Andrographitis has gallbladder benefiting effect and can increase liver weight of rat. The intraperitoneal injection of andrographolide can obviously increase the bile flow of rats. The physical properties of the bile secreted by it are also changed. Andrographolide also resisted hepatotoxic effects of CCl4, D-galactosamine (800mg/kg) and acetaminophen (3g/kg, orally), significantly reduced levels of SGPT, SGOT, SALP, HTG.
The anti-tumor effect is as follows: the dehydroandrographolide succinate has certain inhibition effect on W256 transplanted tumor. Arginine double salt (OASKARG) prepared from potassium dehydroandrographolide succinate has inhibitory effect on DNA synthesis of cultured breast cancer cells.
Disclosure of Invention
The invention provides a method for extracting, separating and purifying andrographolide from andrographis paniculata, and the application of the compound, the pharmaceutically acceptable salt and the pharmaceutical composition thereof in preparing medicaments for treating obesity, abnormal glucose tolerance, hyperlipidemia, diabetes, complications thereof and other diseases, and the application in preparing medicaments for preventing or treating chronic inflammation, insulin resistance, cerebrovascular diseases and atherosclerosis related to the diseases; also provides the application of andrographolide in preparing LTB4 receptor inhibitor.
In order to solve the technical problems, the invention provides the following technical scheme:
the first aspect of the technical scheme of the invention provides an application of andrographolide and pharmaceutically acceptable salts thereof in preparing an LTB4 receptor inhibitor. The andrographolide is characterized by having the following structural formula:
the second aspect of the technical scheme of the invention provides the application of andrographolide shown as the following formula and pharmaceutically acceptable salts thereof in preparing medicines for preventing or treating obesity, insulin resistance, abnormal glucose tolerance, hyperlipidemia, diabetes and complications thereof;
the diabetic complications comprise diabetic nephropathy, diabetic cardiovascular complications, diabetic cerebrovascular diseases, diabetic eye complications or diabetic feet.
The screening of the antidiabetic effect target of the andrographolide is carried out, and the compound is found to have remarkable activity in an LTB4R inhibitor model, so that the effect target of the compound is an LTB4 receptor.
The third aspect of the technical scheme of the invention provides a method for separating and purifying andrographolide from andrographis paniculata, which comprises the following steps:
(1) pulverizing the above-ground medicinal materials of the common andrographis herb, leaching for 3 times with 65% ethanol at 50 ℃, each time for 2 hours, and decompressing and recovering a solvent to 1/10 from an extracting solution at 40-50 ℃ to obtain the crude extract of the common andrographis herb.
(2) Standing the crude extract of herba Andrographitis, separating out crystal, and filtering; further dissolving, decolorizing and recrystallizing to obtain andrographolide.
(3) Performing MCI column chromatography on the crude extract of the andrographis paniculata from which the andrographis paniculata lactone is separated, eluting with 30% ethanol and 50% ethanol, and eluting two column volumes in each gradient, wherein 1/10 in terms of the column volume is used as one flow portion, and 40 flow portions are connected together.
(4) Mixing the fractions eluted with 50% ethanol, concentrating, standing, and separating to obtain andrographolide.
Preferably, the ratio of the mass of the andrographis paniculata medicinal material in the step (1) to the 65% ethanol used each time is 1: 3.5.
Preferably, the solvent is removed in step (1) by rotary evaporation under reduced pressure.
The fourth aspect of the technical scheme of the invention provides application of a pharmaceutical composition in preparing an LTB4 receptor inhibitor, wherein the pharmaceutical composition contains andrographolide with a therapeutically effective dose, pharmaceutically acceptable salts of andrographolide and a pharmaceutical carrier.
The invention also relates to a pharmaceutical composition comprising a pharmaceutically effective amount of said compound and a pharmaceutically acceptable carrier. For this purpose, if desired, in combination with one or more solid or liquid pharmaceutical excipients and/or adjuvants, suitable administration forms or dosage forms for human use are prepared.
According to the present invention, the compounds of the present invention may exist in the form of isomers, and generally, the term "compounds of the present invention" includes isomers of the compounds.
The pharmaceutical compositions of the present invention may be administered in unit dosage form, either enterally or parenterally, for example orally, intramuscularly, subcutaneously, nasally, oromucosally, dermally, peritoneally or rectally, and the like.
The route of administration of the pharmaceutical composition of the present invention may be administration by injection. The injection includes intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, acupoint injection, etc. The administration dosage form can be liquid dosage form or solid dosage form. For example, the liquid dosage form can be true solution, colloid, microparticle, emulsion, or suspension. Other dosage forms such as tablet, capsule, dripping pill, aerosol, pill, powder, solution, suspension, emulsion, granule, suppository, lyophilized powder for injection, etc.
The composition can be prepared into common preparations, sustained release preparations, controlled release preparations, targeting preparations and various microparticle drug delivery systems.
In order to prepare the unit dosage form into tablets, various carriers well known in the art can be widely used. As examples of the carrier, for example, diluents and absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate and the like; wetting agents and binders such as water, ethylparaben, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone, etc.; disintegrating agents such as dried starch, alginates, agar powder, brown algae starch, sodium hydrogen carbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid esters, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors such as sucrose, glyceryl tristearate, cacao butter, hydrogenated oil and the like; absorption accelerators such as quaternary ammonium salts, sodium lauryl sulfate and the like; lubricants, for example, talc, silica, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, and the like. The tablets may be further formulated as coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layered and multi-layered tablets.
For making the administration units into pills, a wide variety of carriers well known in the art can be used. Examples of the carrier are, for example, diluents and absorbents such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc and the like; binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or batter, etc.; disintegrating agents, such as agar powder, dried starch, alginate, sodium dodecylsulfate, methylcellulose, ethylcellulose, etc.
For making the administration unit into a suppository, various carriers well known in the art can be widely used. As examples of the carrier, there are, for example, polyethylene glycol, lecithin, cacao butter, higher alcohols, higher alcohol enzymes, gelatin, semisynthetic glycerase and the like.
To encapsulate the administration units, the active ingredient is mixed with the various carriers described above, and the mixture thus obtained is placed in hard gelatin capsules or soft gelatin capsules. Or making into microcapsule, suspending in aqueous medium to form suspension, or making into hard capsule or injection.
For example, the composition of the present invention is formulated into injectable preparations, such as solutions, suspensions, emulsions, lyophilized powders, which may be aqueous or non-aqueous, and may contain one or more pharmaceutically acceptable carriers, diluents, binders, lubricants, preservatives, surfactants or dispersants. For example, the diluent may be selected from water, ethanol, polyethylene glycol, 1, 3-propanediol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid enzyme, etc. In addition, for the preparation of isotonic injection, sodium chloride, glucose or glycerol may be added in an appropriate amount to the preparation for injection, and conventional cosolvents, buffers, pH adjusters and the like may also be added. These adjuvants are commonly used in the art.
In addition, if desired, colorants, preservatives, flavors, flavorings, sweeteners, or other materials may also be added to the pharmaceutical preparation.
The dose of the pharmaceutical composition of the present invention to be administered depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, body weight, character and individual response of the patient or animal, the administration route, the number of administrations, etc., and thus the therapeutic dose of the present invention can be widely varied. Generally, the dosage of the compounds of the present invention used is well known to those skilled in the art. The actual effective amount of the drug contained in the final preparation of the medicinal composition can be properly adjusted according to the requirement of the effective amount of the drug so as to achieve the treatment of obesity, abnormal glucose tolerance, hyperlipidemia, diabetes, complications thereof and other diseases; and the use of chronic inflammation, insulin resistance, cerebrovascular disease and atherosclerosis in relation to the above mentioned diseases.
In general, for a patient weighing about 75 kg, the compounds of the present invention are administered in a daily dose of 0.001mg/kg body weight to 200mg/kg body weight, preferably 1mg/kg body weight to 100mg/kg body weight. The above-mentioned dosage may be administered in a single dosage form or divided into several, e.g., two, three or four dosage forms, which is limited by the clinical experience of the administering physician and the dosage regimen. The compounds or compositions of the present invention may be administered alone or in combination with other therapeutic or symptomatic agents.
The invention has the beneficial technical effects
The invention discovers that andrographolide separated and purified from andrographis paniculata has an action target of LTB4 receptor for the first time. The invention discovers that andrographolide plays a significant role in reducing blood sugar by regulating LTB4 receptors for the first time. The compound has good application prospect in preparing antidiabetic drugs.
Drawings
The drawings in the present application are intended to provide further explanation of the application, and the illustrative embodiments and description of the application are intended to explain the application and are not to be construed as limiting the application.
FIG. 1 preparation of andrographolide 1 H NMR
FIG. 2 shows the preparation of andrographolide 13 C NMR
FIG. 3 MS of Andrographolide
Figure 4. Andrographolide administration for 2 weeks significantly improved ob/ob mouse glucose tolerance. (A) IPGTT (B) area under the blood glucose curve (C) fasting blood glucose (D) body weight. P < 0.05, P < 0.01, P < 0.001VS control group
Figure 5 andrographolide administration improved ob/ob mouse insulin tolerance for 3 weeks. (A) ITT (B) area under the blood glucose curve. P < 0.05, P < 0.01VS control group
FIG. 6 andrographolide improves ob/ob mouse insulin resistance. (A) Blood glycosylated hemoglobin (HbA1C) (B) blood insulin (C) insulin resistance index. P < 0.05, P < 0.01VS control group
Figure 7 andrographolide administration improved lipid disorders for 4 weeks. (A) Total blood cholesterol (B) low density lipoprotein cholesterol (C) blood triglyceride (D) liver index. P < 0.05, P < 0.01VS control group
Figure 8 andrographolide administration for 4 weeks was shown to improve kidney function in ob/ob mice. (A) Cardiac index (B) blood creatinine. P < 0.05, P < 0.01VS control group
Detailed Description
To further illustrate the present invention, the following detailed description of the invention is given by way of specific examples, which are purely illustrative and intended to describe the invention in detail and not intended to limit the exemplary embodiments according to the application.
Example 1
The preparation method of andrographolide comprises the following steps:
(1) pulverizing 10.0kg of herba Andrographitis, extracting with 65% ethanol at 50 deg.C for 3 times (100L × 3 times) each for 2 hr, and recovering solvent from extractive solution at 40-50 deg.C under reduced pressure to 1/10 (30L) to obtain herba Andrographitis crude extract.
(2) Standing 60L of crude extract of Andrographis paniculata Nees, separating out crystals, and filtering to obtain andrographolide; further dissolving, decolorizing and recrystallizing to obtain 120 g of andrographolide.
(3) Subjecting 5L of crude extract of herba Andrographitis with andrographolide separated out to MCI column chromatography (diameter 15 cm, length 70 cm), eluting with 30% and 50% ethanol, and eluting two column volumes per gradient at flow rate of 120 ml/min; 1/10(1.2 liters) was added in one portion by volume to the column for a total of 40 portions.
(4) Mixing the fractions 26-62 eluted by 50% ethanol, concentrating, standing, and separating out 21 g of andrographolide.
And (3) structural identification: the structure of the separated compound is determined by methods such as nuclear magnetic resonance hydrogen spectrum, nuclear magnetic resonance carbon spectrum, mass spectrum and the like.
Andrographolide: white crystals, HRESI-MS M/z [ M + H ]] + 351.21616, it is suggested that its molecular formula is C 20 H 30 O 5 。 1 H NMR(600MHz,CD 3 OD)δ H 6.83(1H,t,J=6.8Hz,H-12),4.99(1H,d,J=5.8Hz,H-14),4.88(1H,s,H-17a),4.65(1H,s,H-17b),4.45(1H,dd,J=10.5,6.1Hz,H-15a),4.14(1H,d,J=10.5,2.3Hz,H-15b),4.10(1H,d,J=11.4Hz,H-19a),3.39(1H,m,H-3),3.35(1H,d,H-19b),2.59(2H,m,H-11),2.41(1H,t,J=13.1Hz H-7a),2.02(1H,m,H-7b),1.91(1H,d,H-1a),1.81(1H,m,H-2),1.36(1H,m,H-6a),1.29(2H,m,H-9),1.20(3H,s,CH 3 -18),0.74(3H,s,CH 3 -20). 13 C NMR(150MHz CD 3 OD)δ C 37.9(C-1),28.8(C-2),80.7(C-3),43.5(C-4),56.1(C-5),25.0(C-6),38.8(C-7),149.1(C-8),57.2(C-9),39.8(C-10),25.5(C-11),148.6(C-12),129.6(C-13),66.5(C-14),75.9(C-15),172.4(C-16),109.0(C-17),23.2(C-18),64.8(C-19),15.3 (C-20). And documents [ Xiao-HuaWei, Sheng-Jie Yang, Na Liang. chemical Constitutes of Caesalpinia decapetala (Roth) Alston. molecules 2013,18, 1325-; 10.3390/molecules18011325.]The reported data are consistent, and the compound is determined to be andrographolide.
Example 2
Pharmacological experiment: the effect of andrographolide on a LTB4R inhibitor model was determined.
LTB4R is a receptor for leukotriene B4(LTB4) and belongs to the GPCR family. When LTB4 binds to LTB4R, LTB4R recruits the corresponding G-protein G α 16-mediated downstream signaling pathway, resulting in the release of calcium ions from the endoplasmic reticulum into the cytoplasm. The activation of the LTB4R signaling pathway can be determined by detecting a fluorescence signal at 488/525nm, which is emitted by Fluo-8 calcium ion fluorescent chelating agent after binding calcium ions in cytoplasm. When an inhibitor of LTB4R was added, the signaling pathway was not activated and no change in the fluorescence signal was seen.
We treated hamster ovary cancer Cells (CHO) overexpressing LTB4R and G α 16 with DMSO and compound. The degree of calcium signal increase was compared after stimulation with LTB4 by incubating Fluo-8 into the cytoplasm. If the ratio is lower than that of DMSO-treated cells, the compound has a certain inhibitory effect. If it is close to DMSO, no inhibitory effect is indicated. And determining that the compound has no toxicity to cells by using a cell-titer kit, namely proving that the compound has an inhibition effect on LTB 4R.
Experimental sample
Preparation of a tested sample solution: the test sample was andrographolide. An appropriate amount of sample was accurately weighed and prepared into 0.1M stock solution using DMSO for pharmacological activity testing.
Cell line: hamster ovary Carcinoma (CHO) cell
[ test materials and reagents ]:
reagent: fetal bovine serum, DMED medium, DMSO, Fluo-8 NW assay kit, Compound, LTB4, CP-105956
Materials: black 96-well cell culture plate with transparent bottom and 6cm cell culture dish
[ Experimental apparatus ]
CO 2 Incubator, enzyme mark instrument (with titration function)
1. Experimental methods
(1) LTB4R inhibitor modeling:
1) adherent CHO cells in logarithmic growth phase are selected, trypsinized and inoculated in a 6cm cell culture dish by a DMEM culture solution containing 10% fetal bovine serum. When the degree of cell confluence reached 70-80%, 3ug of LTB4R-pReceiver and 1.5ug of G.alpha.16-pReceiver plasmid were transfected into the cells.
2) 36 hours after transfection, cells were harvested by trypsinization and plated in 96-well black clear-bottomed cell culture plates with 50,000 cells per well resuspended in DMEM medium containing 10% fetal bovine serum at 37 ℃ with 5% CO 2 Culturing for 12 h.
3) The next day, the culture medium was replaced with DMEM medium containing 0.5% fetal bovine serum, and DMSO, andrographolide at different concentrations, andrographolide, and positive control were added according to design. 37 ℃ and 5% CO 2 And culturing for 2 h.
4) Add Fluo-8 and incubate for 30 min. Setting an enzyme-labeling instrument, reading a calcium signal in a 6s resting state at 488/525nM, then dropwise adding LTB4 into a cell hole, dropwise adding LTB4 to a final concentration of 400nM, and continuously reading the change of the calcium ion signal after 45s stimulation at 488/525 nM.
(2) Grouping experiments: the experimental group is added with andrographolide with different concentrations, the control group is added with DMSO with the same volume of solvent, and the proportion of the DMSO is not more than 1%.
(3) Detection method of cytotoxicity:
1) a CHO cell line co-expressing LTB4R and ga 16 that can respond to LTB4 was established by the method of step 1) of LTB4R inhibitor modeling.
2) 36 hours after transfection, cells were harvested by trypsinization and plated into 96-well cell culture plates with white transparent bottom at 50,000 cells per well by resuspension in DMEM medium containing 10% fetal bovine serum.
3) Adding DMSO and andrographolide. The final concentration of andrographolide was 10uM and DMSO was added in the same volume. 37 ℃ and 5% CO 2 The culture was carried out overnight.
4) The freshly prepared Cell-titer chemiluminescent detection reagent was added and the fluorescence value was rapidly read by the microplate reader. If the cell dies, the fluorescence value decreases
2. Results of the experiment
[ calculation of results ]
1) Calcium signal increase coefficient (Ca) after 45s calcium signal maximum/first 6s calcium signal average
LTB4R inhibition ratio (%) (Ca) DMSO -Ca Compound (I) )/(Ca DMSO -Ca LTB-free 4 )X 100%
2) Compound toxicity calculation:
toxicity of the compound 1-LUM Compound (I) /LUM DMSO
Through calculation, andrographolide has low toxicity or no toxicity to CHO cells under the concentration of 10 μm, and has obvious inhibiting effect.
The above description is only a preferred example of the present application and is not intended to limit the present application. Any modification, equivalent replacement, improvement and the like made to the present application within the central idea and principle of the present application should be included in the protection scope of the present application.
TABLE 1 Effect of Compounds on CHO cells in the LTB4R inhibitor model
Example 3
1. The experimental method comprises the following steps:
1.1 animal grouping and administration
30 ob/ob mice are randomly divided into 3 groups according to 3 indexes such as fasting blood sugar, body weight, the percentage of blood sugar reduction of insulin tolerance 40min and the like: control group, positive medicine rosiglitazone group (3mg/kg, oral administration, administration volume 0.1ml/10g) and andrographolide (20mg/kg, 0.2ml/10g body weight intraperitoneal injection administration), 10 of each group were administered once a day, and after 2 weeks of continuous administration, intraperitoneal injection glucose tolerance test (IPGTT) was performed. An Insulin Tolerance Test (ITT) was performed 3 weeks after continuous administration. The following materials were drawn after four consecutive administrations, and the heart, liver, blood Total Cholesterol (TC), low density lipoprotein cholesterol (LDL-C), Triglyceride (TG), glycosylated hemoglobin (HbA1C), insulin and creatinine were measured to calculate the insulin resistance index.
1.2 blood glucose testing
The test is carried out by using an ACCU-CHEKPorma of a Roche excellence type blood glucose meter and a matched test strip.
1.3 IPGTT
Animals are fasted for 6h (administration is carried out when the animals are fasted for 5 h), blood sugar is measured for 0min, glucose solution (1g/kg) is administered to abdominal cavity, blood is taken from tail tip to measure blood sugar load, and blood sugar is measured for 15min, 30min, 60min, 90min and 120 min.
1.4 ITT
Animals are fasted for 6h (administration is carried out when fasted for 5 h), blood sugar is measured for 0min, insulin (0.4IU/kg) is injected subcutaneously, blood is taken from tail tips, and blood sugar is measured for 15min, 30min, 60min, 90min and 120min after the insulin is injected.
1.5 TC detection
A10-fold diluted blood sample was taken from the mouse and measured according to the instructions of the kit (Zhongsheng Bei Zhi Biotech Co., Ltd.).
1.6 LDL-C assay
A10-fold diluted blood sample was taken from the mouse and measured according to the instructions of the kit (Zhongsheng Bei Zhi Biotech Co., Ltd.).
1.7 TG detection
A10-fold diluted blood sample was taken from the mouse and measured according to the instructions of the kit (Zhongsheng Bei Zhi Biotech Co., Ltd.).
1.8 HbA1c detection
EDTA anticoagulated whole blood was taken and then measured according to the instructions of the kit (Beijing Haimai bioengineering Co., Ltd.).
1.9 insulin detection
Mouse plasma was diluted 2-fold and then assayed according to kit instructions (ALPCO).
1.10 Creatinine assay
EDTA anticoagulated whole blood was taken and then measured according to the instructions of a kit (Zhongsheng Bei Zhi Biotech Co., Ltd.).
1.11 insulin resistance index calculation
HOMA-IR ═ fasting blood glucose (mmol/l) × fasting insulin (uU/ml)/22.5.
2. Results of the experiment
2.1 As shown in figure 4, after 2 weeks of intraperitoneal administration, the positive drug rosiglitazone significantly improved the glucose tolerance of ob/ob mice, and compared with the control group, andrographolide (20mg/kg) also significantly reduced fasting blood glucose and glucose level after glucose loading of ob/ob mice, improved glucose tolerance, significantly reduced area under the blood glucose curve, and no significant effect on the body weight of mice after 2 weeks of administration.
2.2 As shown in figure 5, after 3 weeks of intraperitoneal administration, 20mg/kg of andrographolide significantly reduced fasting blood glucose in ob/ob mice, improved insulin tolerance in mice, and significantly reduced area under the blood glucose curve compared with the control group.
2.3 As shown in FIG. 6, andrographolide significantly reduced glycosylated hemoglobin levels, as well as hyperinsulinemia and insulin resistance index in ob/ob mice, after 4 weeks of administration. And these effects are comparable to the positive drug rosiglitazone.
2.4 As shown in FIG. 7, the positive drug rosiglitazone significantly increased the blood Total Cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels in ob/ob mice, while andrographolide did not increase LDL-C and also decreased TC. The positive drug rosiglitazone reduces Triglyceride (TG) but increases liver weight significantly, suggesting increased liver lipid synthesis; andrographolide improves triglyceride without increasing liver weight.
2.5 rosiglitazone increased cardiac index in ob/ob mice as shown in FIG. 8, suggesting that rosiglitazone increased edema and cardiac hypertrophy. While andrographolide did not increase the cardiac index of ob/ob mice. Compared with rosiglitazone, andrographolide can also obviously reduce the blood creatinine level of ob/ob mice, and indicates that andrographolide improves the renal function of ob/ob mice.
3. Conclusion of the experiment
(1) The andrographolide administration for 2-4 weeks significantly improved ob/ob mouse insulin resistance. Improving glucose tolerance improves insulin tolerance, and decreases the hyperinsulinemia and insulin resistance index in ob/ob mice.
(2) The andrographolide can be administered for 2-4 weeks to significantly reduce fasting blood glucose of diabetic mice.
(3) Andrographolide administration did not have a significant effect on body weight for 2-4 weeks.
(4) Unlike the positive medicine rosiglitazone, andrographolide can improve lipid disorders of ob/ob mice and reduce cholesterol and triglyceride.
(5) Unlike the positive medicine rosiglitazone, andrographolide does not increase ob/ob cardiac index, and can improve renal function of diabetic mice.
Claims (6)
3. the use according to claim 2, wherein said diabetic complication comprises diabetic nephropathy, diabetic cardiovascular complications, diabetic cerebrovascular disease, diabetic ocular complications or diabetic foot.
4. The application of a pharmaceutical composition in preparing an LTB4 receptor inhibitor is characterized in that the pharmaceutical composition comprises an effective dose of andrographolide and pharmaceutically acceptable salts thereof or pharmaceutically acceptable carriers or excipients.
5. A method for extracting, separating and purifying andrographolide in claim 1 from herba Andrographitis comprises the following steps:
(1) pulverizing the above-ground parts of the andrographis paniculata, leaching the ground parts of the andrographis paniculata with 65% ethanol for 3 times at 50 ℃, each time for 2 hours, and decompressing and recovering the solvent from the extract at 40-50 ℃ to 1/10 to obtain an andrographis paniculata crude extract;
(2) standing the crude extract of herba Andrographitis, separating out crystal, and filtering; further dissolving, decolorizing and recrystallizing to obtain andrographolide;
(3) carrying out MCI column chromatography on the crude extract of andrographis paniculata from which andrographolide is separated, eluting with 30% and 50% ethanol, eluting two column volumes in each gradient, and collecting 40 parts of the flow according to 1/10 serving as one part of the column volume;
(4) mixing the fractions eluted with 30% ethanol, concentrating, standing, and separating to obtain andrographolide;
(5) mixing the fractions eluted with 50% ethanol, concentrating, standing, and separating to obtain andrographolide.
6. The method of claim 5, wherein the weight to volume ratio of the mass of the Andrographis paniculata Nees herb to the 65% ethanol used per time to the solvent in step (1) is 1: 10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110275769.4A CN115068467A (en) | 2021-03-15 | 2021-03-15 | Medical application of andrographolide as LTB4 receptor inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110275769.4A CN115068467A (en) | 2021-03-15 | 2021-03-15 | Medical application of andrographolide as LTB4 receptor inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115068467A true CN115068467A (en) | 2022-09-20 |
Family
ID=83240666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110275769.4A Pending CN115068467A (en) | 2021-03-15 | 2021-03-15 | Medical application of andrographolide as LTB4 receptor inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115068467A (en) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009698A1 (en) * | 2000-08-01 | 2002-02-07 | Ashni Naturaceuticals, Inc. | Compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
CN101125850A (en) * | 2007-08-08 | 2008-02-20 | 暨南大学 | Andrographolide derivatives and application of the same in pharmacy |
CN101264122A (en) * | 2007-03-16 | 2008-09-17 | 中国医学科学院药物研究所 | Hypericum extract, its making method and medicinal composition and use for treating diabetes |
CN101485646A (en) * | 2009-02-12 | 2009-07-22 | 吉林大学 | Andrographolide catablasm and preparation method thereof |
CN101559088A (en) * | 2009-05-21 | 2009-10-21 | 雷允上药业有限公司 | Production technique of andrographolide and neoandrographolide, dehydroanddrographolide, oxyandrographolide |
CN101683334A (en) * | 2002-03-20 | 2010-03-31 | 细胞基因公司 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
CN102046167A (en) * | 2008-03-27 | 2011-05-04 | 细胞基因公司 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
CN102247356A (en) * | 2011-07-12 | 2011-11-23 | 上海中医药大学 | Use of andrographolides |
CN102898349A (en) * | 2008-03-27 | 2013-01-30 | 细胞基因公司 | Solid containing compound, a composition containing the solid and use of the solid |
CN106822166A (en) * | 2017-01-24 | 2017-06-13 | 中国科学院昆明植物研究所 | A kind of medicine and its application in pharmacy for preventing and treating diabetes and hyperlipidemia |
TW201808319A (en) * | 2016-09-05 | 2018-03-16 | 科鼎國際有限公司 | Use of composition of active ingredients in organic extract of Andrographis paniculata in treating hyperlipidemia |
CN110538175A (en) * | 2019-08-09 | 2019-12-06 | 中国中医科学院广安门医院 | Application of andrographolide in preparing accelerant for promoting reverse cholesterol transport |
TW202000209A (en) * | 2018-06-25 | 2020-01-01 | 馬來西亞商科鼎國際有限公司 | Use of composition of Neoandrographolide in lowering blood sugar |
-
2021
- 2021-03-15 CN CN202110275769.4A patent/CN115068467A/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009698A1 (en) * | 2000-08-01 | 2002-02-07 | Ashni Naturaceuticals, Inc. | Compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
CN101683334A (en) * | 2002-03-20 | 2010-03-31 | 细胞基因公司 | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
CN101264122A (en) * | 2007-03-16 | 2008-09-17 | 中国医学科学院药物研究所 | Hypericum extract, its making method and medicinal composition and use for treating diabetes |
CN101125850A (en) * | 2007-08-08 | 2008-02-20 | 暨南大学 | Andrographolide derivatives and application of the same in pharmacy |
CN102046167A (en) * | 2008-03-27 | 2011-05-04 | 细胞基因公司 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
CN102898349A (en) * | 2008-03-27 | 2013-01-30 | 细胞基因公司 | Solid containing compound, a composition containing the solid and use of the solid |
CN101485646A (en) * | 2009-02-12 | 2009-07-22 | 吉林大学 | Andrographolide catablasm and preparation method thereof |
CN101559088A (en) * | 2009-05-21 | 2009-10-21 | 雷允上药业有限公司 | Production technique of andrographolide and neoandrographolide, dehydroanddrographolide, oxyandrographolide |
CN102247356A (en) * | 2011-07-12 | 2011-11-23 | 上海中医药大学 | Use of andrographolides |
TW201808319A (en) * | 2016-09-05 | 2018-03-16 | 科鼎國際有限公司 | Use of composition of active ingredients in organic extract of Andrographis paniculata in treating hyperlipidemia |
CN106822166A (en) * | 2017-01-24 | 2017-06-13 | 中国科学院昆明植物研究所 | A kind of medicine and its application in pharmacy for preventing and treating diabetes and hyperlipidemia |
TW202000209A (en) * | 2018-06-25 | 2020-01-01 | 馬來西亞商科鼎國際有限公司 | Use of composition of Neoandrographolide in lowering blood sugar |
CN110538175A (en) * | 2019-08-09 | 2019-12-06 | 中国中医科学院广安门医院 | Application of andrographolide in preparing accelerant for promoting reverse cholesterol transport |
Non-Patent Citations (5)
Title |
---|
ISLAM MT: "Andrographolide, a New Hope in the Prevention and Treatment of Metabolic Syndrome", FRONT PHARMACOL, vol. 8, pages 4 - 8 * |
YU Z,等: "Andrographolide ameliorates diabetic retinopathy by inhibiting retinal angiogenesis and inflammation", BIOCHIM BIOPHYS ACTA, vol. 1850, no. 4, pages 824 - 831, XP029139315, DOI: 10.1016/j.bbagen.2015.01.014 * |
ZHAI Z,等: "Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling", BREAST CANCER RES TREAT, vol. 144, no. 1, pages 33 - 45 * |
李斌,等: "穿心莲内酯药理作用研究进展", 赣南医学院学报, vol. 35, no. 03, pages 3 * |
王佳佳,等: "不同Wagner分级糖尿病足与甲状腺功能的临床研究", 中华老年多器官疾病杂志, vol. 15, no. 07, pages 537 - 542 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102526165B (en) | A kind of Radix Rhodiolae effective site, its preparation method, its pharmaceutical composition and purposes | |
CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
EP2664361A1 (en) | Extract of fraxinus excelsior seeds and therapeutic applications therefor | |
CN106220701B (en) | triterpene compound and preparation method and application thereof | |
WO2022257995A1 (en) | Cryptotanshinone derivative and preparation method therefor and application thereof in lowering lipid and resisting obesity | |
CN101537046A (en) | Blood lipid-lowing active fractions of forsythia suspensa and preparation method and use of same | |
CN101570557B (en) | Compound in cyclocarya paliurus and application thereof in medicament field | |
KR20200055767A (en) | Baekbongchae total flavonoid extract and its preparation method and use for treating non-alcoholic fatty liver | |
US20230398168A1 (en) | Use of effective part extract of monochasma savatieri in preparation of drug for treating inflammatory disease or tumor | |
CN110123827A (en) | A kind of pharmaceutical composition and its preparation method and application treated by metabolic disorder associated diseases | |
CN106928299B (en) | Compound from cortex lycii radicis, preparation method and application thereof in aspect of reducing blood sugar | |
CN115068486A (en) | Application of boswellic acid compounds as LTB4 receptor inhibitors | |
CN115068467A (en) | Medical application of andrographolide as LTB4 receptor inhibitor | |
KR100979459B1 (en) | Tetracera scandens extracts and 4H-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated L6 muscle cells | |
CN115068491A (en) | Medical application of andrographolide as LTB4 receptor inhibitor | |
CN106822095B (en) | Medicine for preventing and treating fatty liver and obesity and application thereof in pharmacy | |
CN102266567B (en) | Radix scutellariae extractive phospholipid complex, and preparation method and purpose thereof | |
CN102240293B (en) | Application of echinocystic acid in preparing medicament preventing and treating cardiovascular diseases | |
CN108403683A (en) | Application of the rosin spirit in preparing the product that prevention oxidative stress induces an illness | |
CN106554349A (en) | Wild anistree new isopentene group replaces C6‑C3Class compound and preparation method thereof, application and its pharmaceutical composition | |
CN106543133A (en) | Wild anistree new isopentene group replaces C6‑C3Class compound and preparation method thereof, application and its pharmaceutical composition | |
CN103393637B (en) | Use of flavonoid compound in preparation of metabolic disease resistance medicines | |
CN114246873A (en) | Use of compounds and extracts derived from antrodia camphorata as FGF21 agonists and therapeutics or prophylactics for related diseases | |
CN102579422B (en) | Application of flavonoids compound in preparation of anti-metabolic disease medicine | |
CN102040603B (en) | The purposes of the adjacent methoxycarbonyl benzyl tetrahydro Berberine of bromination N-and treatment hyperlipidemia thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220920 |
|
WD01 | Invention patent application deemed withdrawn after publication |